Imbue Botanicals, LLC has signed a Co-Marketing agreement with Endocanna Health, Inc.

Imbue Botanicals

Endocanna Health DNA Test Kit

Imbue Botanicals to Co-Market CBD Products with DNA Tester Endocanna Health

PALM SPRINGS, CA, UNITED STATES, October 16, 2018 /EINPresswire.com/ — FOR IMMEDIATE RELEASE…Palm Springs, CA, October 11, 2018 – (Press Release Point) – Imbue Botanicals LLC, a Wyoming based company, has finalized an agreement with California-based Endocanna Health to co-market direct-to-consumer CBD products—and to co-market to one of Imbue’s major domains—the independent pharmacy arena.

Imbue Botanicals offers an extensive line of premium CBD products produced from organically grown Colorado hemp, including CBD tinctures, lotions, salves and capsules, for both people and pets.

Endocanna Health is the maker of the "Cannabinoid DNA Variant Test™"—the most comprehensive personalized cannabis DNA test on the market today. Developed by a team of specialists and scientists at Endocanna Heath, a biotechnology research company, this direct-to-consumer DNA test kit analyzes an individual's DNA markers and provides them with science-backed consumer recommendations based on their specific DNA.
“We're excited about introducing Imbue Botanicals to our customers, and look forward to working with Imbue’s independent pharmacy and retail clientele to help them make more informed buying decisions,” said Len May, Endocanna Health co-founder and CEO. “This co-marketing agreement will benefit both companies and will provide many alternative health solutions for our customers. We wanted a CBD product line to partner with that was U.S. grown and manufactured, a partner with innovative designs and branding, and above all, a partner with an efficacy that matches our corporate philosophy. We found that in Imbue Botanicals.”

“We’re thrilled to be aligned with such a forward-thinking company like Endocanna Health,” said Tom Bauer, Managing Partner for Imbue Botanicals. “Having this kind of arrangement for two companies that are so committed to patient care is truly a win-win.”

The co-marketing agreement begins this month.

ABOUT Imbue Botanicals, LLC:
Imbue Botanicals offers an extensive line of full spectrum, premium CBD products produced from organically grown Colorado hemp, including tinctures, capsules, topical CBD lotions and salves. Their premium Colorado grown hemp CBD products are non GMO, cruelty free, vegan and contain no added flavorings or sugars. Available through select retailers, their products offer exceptional quality, superb packaging and unmatched value.

Imbue Botanicals offers CBD products for both people and pets. For more information, visit: www.imbuebotanicals.com
Facebook: www.facebook.com/imbuebotanical
Instagram: www.instagram.com/imbuebotanicals_cbd

ABOUT Endocanna Health, Inc.:
Endocanna Heath is a biotechnology research company that utilizes a patent-pending algorithm and process for its Cannabinoid DNA Variant Report™. DNA for the test is obtained through either a simple saliva swab or existing genetic data from popular DNA testing services like Ancestry, 23andMe, Family TreeDNA, or MyHeritageDNA. For a full spectrum experience, consumers can use their personalized reports to discover the right products for their specific genetics with product suggestions from Endocanna Health. For more information, visit:
www.endocannahealth.com
Instagram: @endocanna_health
Facebook: Endocanna Health

Paul Caudell
Joseph Allen Agencies, LLC
760-318-5401
email us here


Source: EIN Presswire

Intermountain Precision Genomics Launches NGS ONE Genomics Services

SALT LAKE CITY, UTAH, USA, October 16, 2018 /EINPresswire.com/ — Intermountain Precision Genomics has launched NGS ONE™ Genomics Services to empower researchers with uniquely intuitive and cost-effective services for their next generation sequencing studies in precision medicine, translational science and clinical research. This new service allows customers to request kits, obtain quotes and place orders online, with data made available via a secure cloud-based portal.

Helaman Escobar, Director of Intermountain’s Translational Science Center said, “We are thrilled to offer access to the technology and expertise of our high-throughput genomics center to a broader audience of clinicians and researchers.” Escobar adds “We specifically designed the NGS ONE™ service to be simple and intuitive to deliver solutions at scale for studies in precision medicine, research and other fields of science. The service is offered at an attractive price while providing a unique, collaborative environment for outside investigators to work directly with our scientists.”

NGS ONE™ supports projects where whole genome, human whole exome and RNASeq experiments are required. With options available that provide the best combination of pricing, data yields and high sample throughput, NGS ONE™ is designed to accommodate projects of different types and sizes. It aligns with Intermountain Healthcare’s commitment to helping people live the healthiest lives possible by advancing molecular knowledge in health and disease.

Intermountain Precision Genomics and NGS ONE™ are services provided by Intermountain Healthcare. Working at the forefront of medical science and technology, Intermountain Precision Genomics leverages the power of next-generation sequencing and state-of-the art genomic technology to enable translational research. Intermountain Healthcare is widely recognized as leader in clinical improvement and transforming healthcare through high quality and sustainable costs. For more information about NGS ONE™, visit: www.ngsone.org or ngsone@imail.org, or call (833) 4-NGSONE.

Daron Cowley
Intermountain Healthcare
801-442-2834
email us here


Source: EIN Presswire

Treasure hunting exploration company, Global Marine Exploration Inc. brings action against State of Florida DOS.

Bobby Pritchett CEO of Global Marine Exploration "You cannot trust the State of Florida, or at least the people whom run it, very dishonest and misleading.IMO

CAPE CANAVERAL, FLORIDA, BREVARD, October 16, 2018 /EINPresswire.com/ — THE CIRCUIT COURT OF THE EIGHTEENTH JUDICIAL CIRCUIT
IN AND FOR BREVARD COUNTY, FLORIDA
Over a period of time, the Division issued GME six exploration permits with dig addenda for different three-square areas off the coast of Cape Canaveral. These turned up shipwreck evidence (anchors) but mostly resulted in identification of rocket debris.
12. The Florida Department of Environmental Protection, Division of State Lands, provided salvage easements for GME to use State-owned submerged lands for the areas and time periods for which the Division agreed for GME to explore for and recover shipwreck sites.

13. The Florida Department of Environmental Protection and the Federal Corps of Engineers contemporaneously issued construction permits to GME for it to use the designated submerged lands and navigable waters above for exploration and salvage.
14. On August 14, 2015, upon detailed application by GME, the Division issued a seventh Exploration Permit (# 2015-03) for GME to explore another three-square mile area of State waters in the Cape Canaveral vicinity to locate and report information about shipwreck sites in that designated area.
15. In proceeding with respect to Permit # 2015-03, as amended, GME discovered at least five separate locations of apparently distinct shipwreck sites which GME reported to the State as agreed. The locations of the discovered shipwreck sites and the methods used to identify those locations were proprietary, confidential trade secret information, and there is no requirement or agreement for public disclosure of such information.
16. GME provided site locations to the Division only after the Division repeatedly assured GME that this proprietary information would be maintained confidential and not disclosed to third-parties or used without GME’s consent.
17. On August 19, 2015, the Division issued Amendment One of Exploration Permit # 2015-03, recognizing GME’s successful completion of sensing survey within the designated area, allowing activity to identify newly uncovered cultural materials and limited test excavation and diagnostic artifact recovery for shipwreck identification purposes, and specifying that recovered artifacts would be included in the pool of artifacts considered for transfer to GME if a recovery permit is issued in the future for the same area. This Amendment explicitly authorized recovery of shipwreck artifacts, and promised to pool their value with the value of all ultimately recovered objects to calculate 80% thereof to be paid to GME.
18. On September 9, 2015, the Florida Department of Environmental Protection issued Notice of Modification of its construction permit to include areas approved by Exploration Permit # 2015-03, reciting that the modification includes amendment of the easement for treasure salvage investigations to include the new approved area.
19. On December 7, 2015, the State executed a Modified Sovereignty Submerged Lands Cultural Resource Recovery Easement for Salvage Exploration and Operation Purposes, stating that it was “for salvage operations only,” that “any artifacts or materials recovered by the applicant shall be disposed of pursuant to the contract issued by the Department of State;” and that the easement was “valid only after the Department of State has issued a contract for exploration or salvage and shall remain valid only so long as the Department of State’s contract is in full force and effect.”
20. Copies of the Division’s Exploration Permit # 2015-03, Amendment One, the Florida Department of Environmental Protection Salvage Work Permit Modification, and the State’s “Modified Sovereignty Submerged Lands Cultural Resource Recovery Easement for Salvage Exploration and Operation Purposes” for the approved area are attached as Exhibits A-1, A-2, A-3, and A-4, respectively.
21. GME recovered certain items and provided recorded identification of certain cannons and monuments to the Division by photograph and video.
22. GME made proper application for a recovery permit to authorize full recovery of artifacts from the discovered shipwreck sites.
23. The Division had never raised an issue nor made any negative response as to any work not having been done, or done improperly, in connection with any GME permit requirement.
24. GME became concerned when it learned that the Division considered that identified artifacts from one of the sites were from an old French naval ship and was negotiating the shipwreck finds with France for it to claim without GME’s involvement or consent.
25. GME filed a federal court complaint in admiralty in rem against “The Unidentified, Wrecked and (for Finders-Right Purposes) Abandoned Sailing Vessel,” seeking to establish its ownership under the Law of Finds.
26. Incident to its filing of this action, GME was required to deposit recovered artifacts under the federal court’s control.
27. The Division demanded that GME turn over those recovered artifacts, but GME could not comply because the federal court controlled the property.
28. The Division then suspended GME’s exploration permit and would not issue a recovery permit to GME, stating that the only cure was for possession of the artifacts recovered for identification purposes to be delivered to the Division.
29. The federal court transferred control of the identified artifacts to the Division, fulfilling this demand; however, the Division still refused or otherwise failed to reinstate GME’s exploration permit so it could identify artifacts at the other discovered sites, and refused to issue a recovery permit for it to complete recovery of the finds.
30. The Division’s actions caused GME significant loss and deprived GME from realizing compensation value from shipwreck sites and artifacts it discovered, contrary to GME’s investment-backed expectations in undertaking salvage operations

Robert Pritchett
Global MArine Exploration Inc
772-205-8184
email us here


Source: EIN Presswire

Global Cryonics Technology Market Research and Forecast 2018-2023

Global Cryogenic Technology Market

Orion Market Research

Global Cryonics Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023

Increasing demand for living cell preservation augmenting the growth”

— OMR Analyst

INDORE, INDIA, October 16, 2018 /EINPresswire.com/ — According to OMR analysis, the global cryonics technology market is expected to grow at a moderate CAGR during the forecast period 2018-2023. The cognitive computer market is estimated to grow modestly during the forecast period due to growing applications of the technology in healthcare industry to meet the medical necessity for creating the cryonic temperature to preserve the organs and chemicals. The global cryonics technology market can be bifurcated into by cryoprotective agents, which is further segmented into permeating cryoprotectants and non-permeating cryoprotectants; by method, it is segmented into slow freezing, vitrification and rapid freezing; by application, the market is further bifurcated into animal husbandry, fishery science, medical science, preservation of microbiology culture, and conserving plant biodiversity; by end-user, market is further classified into life science and healthcare facilities, and research laboratories; and by geography, it is further segmented into North America, Europe, Asia-Pacific and Rest of the World. The report provides detailed and insightful chapters which includes market overview, key findings, strategic recommendations, market estimations, market determinants, key company analysis, market insights, company profiling, market segmentation, geographical analysis, analyst insights and predictive analysis of the market.

Full report of global cryonics technology market is available at https://www.omrglobal.com/industry-reports/cryopreservation-system-market/

Cryonics is living cells preservation technology that operates by creating extreme low temperature. Its applications are not only limited to human living cells but animal cells also. One of the growing factor for the cryonics technology market is increasing demand for organ transplantation due to increased organ surgeries. Major challenge for the market players is the dearth of skilled or qualified cryonic practitioners and government agenda framing stringent regulations for the practice of cryonics technology.

North America is leading the cryonics & cryogenic technology market with increased adoption of technology for animal husbandry and human living cells. Europe is the second largest region in the market share due to medical advancements in the region of Europe for organ preservation. With rising organ donation trend in the region of Asia-Pacific. Asia-Pacific is the fastest growing region due to adoption of technology because of stop aging process.

The report covers
Comprehensive research methodology of Global Cryonics
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global Cryonics Market.
Insights about market determinants which are stimulating the Global Cryonics
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

For related reports please visit https://www.omrglobal.com/reports-category/advanced-technologies/

About Orion Market Research
Orion Market Research (OMR) a research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company aims to provide business insights for decision making to the global clients and offers quality syndicated research reports, customized research reports, Company profiling, consulting and other research-based services. OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles.

Anurag Tiwari
Orion Market Research Pvt. Ltd.
+919179828694
email us here
Visit us on social media:
LinkedIn

Global Cryogenic Technology Market Research By OMR


Source: EIN Presswire

Global Cognitive Computer Market Research and Forecast 2018-2023

Global Cognitive Computing Market

Orion Market Research

Global Cognitive Computing Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023

Cognitive computer market to mark substantial growth due to growing number of end-user industries, and economic & efficient technology demand”

— OMR Analyst

INDORE, INDIA, October 16, 2018 /EINPresswire.com/ — According to OMR analysis, the global cognitive computer market is expected to grow at a moderate CAGR during the forecast period 2018-2023. The cognitive computer market is estimated to grow modestly during the forecast period due to increasing adoption of the technology in end-user industries to facilitate the integration of human and computer with software services. The global cognitive computer market can be bifurcated into by technology, which is further segmented into natural language processing, machine learning, automated reasoning and others (information retrieval); by deployment, it is segmented into cloud and on premises by vertical, the market is further bifurcated into aerospace & defense, BFSI (Banking, Financial Services and Insurance), telecom & IT, consumer goods & retail, energy & power, tourism & travel, media & entertainment, education & research and others; and by geography, it is further segmented into North America, Europe, Asia-Pacific and Rest of the World. The report provides detailed and insightful chapters which includes market overview, key findings, strategic recommendations, market estimations, market determinants, key company analysis, market insights, company profiling, market segmentation, geographical analysis, analyst insights and predictive analysis of the market.

Full report of global cognitive computer market is available at: https://www.omrglobal.com/industry-reports/cognitive-computing-market/

Cognitive computing is the technology platform which is based on artificial intelligence, machine learning and signal processing. The technology enables the human-computer interaction in more efficient manner due to integration of AI and machine learning with it. Use cases of the technology are face detection, speech recognition, sentimental analysis, fraud detection and risk management. Some of the major IT development in the field of cognitive computing made by software giants to solve real life problems are Vantage Software, CaféWell Concierge, Sofie, BrightMinded, WayBlazer, and Edge Up Sports. Technological advancements of the artificial intelligence, one of the key aspects of cognitive computing, led to rise in the investment of $5.1 billion in the year of 2016. Major breakthrough of cognitive computing is in the sector of healthcare where it facilitates to reduce cost by automating task such as de-identifying patient care records, and reviewing prior authorization requests. Along with its numerous benefits, cognitive computing face challenge of training process to tune the software system to work efficiently.

By geography North America is estimated to be the dominating region in the global cognitive computer market due to presence of established market players and growth in the artificial intelligence. North America is followed by Europe and Asia-Pacific. Asia-Pacific is the fastest growing region due to growth in Information Technology industry in the developing countries such as India and China.

The report covers
Comprehensive research methodology of global Cognitive Computing Market.
This report also includes detailed and extensive market overview with analyst insights & key market trends.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global Cognitive Computing Market.
Insights about market determinants which are stimulating the global Cognitive Computing Market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

For related reports please visit: https://www.omrglobal.com/reports-category/advanced-technologies/

About Orion Market Research
Orion Market Research (OMR) a research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company aims to provide business insights for decision making to the global clients and offers quality syndicated research reports, customized research reports, Company profiling, consulting and other research-based services. OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles.

Anurag Tiwari
Orion Market Research Pvt. Ltd.
+919179828694
email us here
Visit us on social media:
LinkedIn

Global Cognitive Computer Market Research By OMR


Source: EIN Presswire

Global Genome Editing Market Research and Forecast 2018-2023

Global Genome Editing Market

Orion Market Research

Genome editing market, size, share, market intelligence, company profiles, market trends, strategy, research report, analysis, forecast 2018-2023

Increasing funding for genome editing research is primarily driving the global genome editing market”

— OMR Analyst

INDORE, INDIA, October 16, 2018 /EINPresswire.com/ — According to OMR analysis, the global genome editing market is expected to grow significantly during the forecast period (2018-2023) coupled with increasing funding for genome editing research. Additionally, the global genome editing market is segmented on the basis of technologies, application, end-users and regional outlook. The report provides detailed & insightful chapters which include market overview, key findings, strategic recommendations, market estimations, market determinants, key company analysis, market insights, company profiling, market segmentation, geographical analysis, patent analysis, analyst insights and predictive analysis of the market.

Full report of global genome editing market is available at: https://www.omrglobal.com/industry-reports/genome-editing-market/

Increasing funding for genome editing research is primarily contributing towards the market growth. National Institute of Health (NIH) has declared a plan in Jan 2018 to fund $190 million for research in genome editing. It is an effort intended for removing restrictions that reduces the use of genome editing for the treatment of patients. This new program named Somatic Cell Genome Editing by NIH will grant funding to the biomedical researchers in the six years from the beginning of 2018. These biomedical researchers will work together to improve the delivery mechanisms that enables to target gene editing tools among patients and develop new and advanced genome editors. In addition, they will develop assays to test the safety and effectiveness of the genome editing tools in human and animal cells as well as assemble a genome editing toolkit that will contain subsequent tools, methods and knowledge to be shared with the scientific community.
Moreover, in June 2018, Precision Biosciences, Inc. (a US-based biotechnology firm) closed an oversubscribed series B funding of $110 million. This funding is aimed for efforts on product development which is based on its platform, ARCUS genome editing. The funding was led by ArrowMark Partners and other new investors such as Franklin Templeton Investments, Cowen Healthcare Investments and Adage Capital Management. This is intended to broaden the applications of its genome editing platform, ARCUS in the areas of genetic disease and immuno-oncology, which in turn is expected to lead the way for the company to set up as a wholly integrated biotechnology firm. they will use this funding to leverage and expanding its product portfolio. Such kinds of funding activities are showing increasing focus on genome editing techniques, which in turn will lead to propel the market growth.

The report covers
Comprehensive research methodology of global Genome editing market.
In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global genome editing market.
Insights about market determinants which are stimulating the global genome editing market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

For related reports please visit: https://www.omrglobal.com/reports-category/biotechnology/

About Orion Market Research
Orion Market Research (OMR) a research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company aims to provide business insights for decision making to the global clients and offers quality syndicated research reports, customized research reports, Company profiling, consulting and other research-based services. OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles.

Anurag Tiwari
Orion Market Research Pvt. Ltd.
+919179828694
email us here
Visit us on social media:
LinkedIn

Global Genome Editing Market Research By OMR


Source: EIN Presswire

Dr. Elissa J. Santoro to be Featured on CUTV News Radio

LIVINGSTON, NEW JERSEY, UNITED STATES, October 16, 2018 /EINPresswire.com/ — When caught early, about 90 percent of women diagnosed with breast cancer will live a full life. If caught at Stage 0, then almost 100% are cured. 50 years ago, however, four out of five patients were dead within five years. There were no mammograms at that time for early detection and almost no attention had been paid to supporting patients emotionally as well as physically throughout treatment.

But that all changed slowly but surely thanks to the efforts of pioneering physicians like Dr. Elissa Santoro. A surgical oncologist since 1970, today Dr. Elissa Santoro serves as Breast Care Consultant for RWJS Barnabas Health Center. Now 80 years old, and no longer performing surgery, Dr. Santoro care for even more patients than ever while teaching the next generation of surgical oncologists all she has learned as a practicing physician.

“Medicine is really a healing art as well as a science,” says Dr. Santoro. “I had always wanted to be a healer and not just a technician because no doctor has yet cured mortality, so while we're here, our focus should be on quality of life.”

Dr. Santoro has been on the front lines as the field of cancer treatment has evolved. In fact, she has been responsible for much of that evolution, and the approach to care those who have been diagnosed can receive today. When integrative medicine was still in its infancy, Dr. Santoro pioneered a holistic integrative breast care for women, immersing patients into compete healing of mind, body and spirit.

“As the only woman surgical oncologist in New Jersey, I found there was a terrible need for a more holistic approach,” says Dr. Santoro. “I had the ability to open up a practice for breast care and treatment center where the patient could be diagnosed, operated on if needed, chemotherapy if needed, as well as treating the mind, body, and spirit. That’s what was missing. In that era being told you had breast cancer, meant you would die in five years and suffer through mutilating surgeries like radical mastectomies. I would refer them for counseling, for healing. If they had a religion, I'd get the support of their pastors or rabbis.”

And as the field has evolved, women have shown they want women to be their doctor.

“The breast is very symbolic,” says Dr. Santoro, “so it's a great field for a woman because we can better understand the psychosexual component of this diagnosis. It affects marriages, relationships.

“We've come a long, long way and there's so much on the horizon,” says Dr. Santoro. “We're learning more and more about the immune cells and identifying the patients at risk using gene testing. Maybe one day surgery will have only minor role, but it's been a big change from 1970 to 2018.”

CUTV News Radio will feature Dr. Elissa J. Santoro, MD., FACS in an interview Jim Masters on October 18th at 12pm EDT.

Listen to the show on BlogTalkRadio. If you have a question for our guest, call (347) 996-3389.

For more information on Dr. Elissa J. Santoro, MD., FACS, visit www.elissa-santoro1.info

Lou Ceparano
CUTV News
(631) 850-3314
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

Infection specialists at IDWeek conference keen to investigate microbes as triggers of Alzheimer’s disease

A new wave of interest in exploring the possibility a microbe is the trigger in Alzheimer's is rising in the infectious diseases community.

Many attendees told us they had privately noticed similarities between Alzheimer’s and various less-common infections, but there had been no channels through which to express this growing awareness.”

— Dr. Leslie Norins

NAPLES, FL, UNITED STATES, October 16, 2018 /EINPresswire.com/ — More than 1,000 infectious disease specialists attending IDWeek 2018 in San Francisco feel it is time for deeper research into the role infectious agents play in triggering and accelerating Alzheimer’s disease, said Leslie Norins, M.D., Ph.D., CEO of Alzheimer’s Germ Quest, Inc., upon his return from the conference.

Dr. Norins based his conclusion on conversations with attendees and the number of copies of his White Paper “It’s Time to Find the Alzheimer’s Germ” which were taken by attendees at the conference, the leading annual gathering of clinicians and researchers who focus on infectious diseases. “Many also told us they had privately noticed similarities between Alzheimer’s and various less-common infections, but there had been no channels through which to express this growing awareness.”

He explained that evidence for infectious triggers of Alzheimer’s has been published over the years but this possibility has been largely ignored by research funders in government and advocacy groups. They instead favored studies of the amyloid plaques and tau tangles which are prevalent in Alzheimer’s brains.

“Day versus night,” was how Dr. Norins compares the IDweek interest to that he observed at the “AAIC” Alzheimer’s conference in Chicago a few weeks earlier. He attributed this difference to the fact that while existing ALZ researchers are well versed in neurology and neuroscience, few are expert in the clinical and lab aspects of infectious diseases.

He says there’s a new wave of Alzheimer’s interest rising in the infectious diseases community, especially since after decades of research and billions of dollars spent on amyloid plaques and tau the root cause of the killer disease remains a mystery and there is still no drug to cure it.

The Foundation of the Infectious Diseases Society of America is currently offering two grants for research on infectious causation of Alzheimer’s, funded by Alzheimer’s Germ Quest.

Alzheimer’s Germ Quest, Inc. is a public benefit corporation headquartered in Naples Florida, devoted to widening and accelerating research into infectious agents as triggers for Alzheimer’s disease. It is self-funded, and neither solicits nor accepts outside donations.

Mollie Page
2397777243
email us here
Alzheimer's Germ Quest


Source: EIN Presswire

Kepley BioSystems Presents Sustainable Crayfish Biology at BugFest 2018

Each year over 35,000 visitors come to BugFest to experience over 100 exhibits, crafts, games and activities. The venue provides the opportunity for attendees to interact with entomologists, scientists and learn about the fascinating world of bugs.

2018 Theme Arthropod: Crayfish and Other Crustaceans

Cammie the Crawfish Presents: Sustainable Science and Technologies- Come and meet Cammie and learn about how she is helping to protect the environment and preserve ancient species! Cammie is a Rocky River Crayfish raised in KBI labs in Greensboro, N.C.

Pictured holding an American Lobster and OrganoBait™, a synthetic and sustainable alternative bait that attracts crustaceans funded by the National Science Foundation, North Carolina Sea Grant and One N.C. Small Business Program.

Anthony Dellinger, PhD and President of Kepley BioSystems will be speaking in the SECU Daily Planet Theater at Bugfest 2018 on Saturday, October 20, 2018 at 10:30AM.

GREENSBORO, NORTH CAROLINA, UNITED STATES, October 15, 2018 /EINPresswire.com/ — Kepley BioSystems (KBI) is pleased to have been selected for a BugFest 2018 presentation and corporate participant. BugFest is hosted by the North Carolina Museum of Natural Sciences and attracts over 35,000 visitors to experience exhibits, crafts, games and activities every year. The event brings scientists and the public together to learn and experience the remarkable world of bugs! The festival will be held on Saturday, October 20, 2018, in Raleigh, North Carolina. The Kepley presentation is scheduled for 10:30 am in the SECU Daily Planet Theater in the Nature Research Center.

The BugFest theme this year is “Arthropods – Crayfish and Other Crustaceans”; crayfish will be featured along with other arthopods, including insects, arachnids, and myriapods. KBI President, Dr. Anthony Dellinger, will kick off the presentations with a talk entitled, “Who’s Your Crawdaddy? Capturing Crayfish While Saving the World’s Baitfish.” This story of science and nature will highlight how the tiny crayfish is helping advance research to sustainably restore the ocean’s most vital resource – forage fish.

Members of the KBI team will be on hand to meet with visitors at the exhibit, “Cammie the Crawfish Presents: Sustainable Science and Technologies” (Nature Research Center – 3rd Floor, Booth #104). Cammie the Crawfish will be the featured guest, and visitors can learn how she is helping protect the environment and preserve vital ocean species.

“Kepley BioSystems is excited to participate in BugFest this year, particularly with the emphasis on arthropods. We’re looking forward to sharing our technologies – and to introducing our ten-legged team member, Cammie, to the public!” said KBI research scientist, Lee Robertson.

This year’s event will include Café Insecta where patrons will be introduced to the practice of eating bugs prepared by local chefs. In all, more than 100 exhibits will offer entomology-based education, crafts and games sure to entertain even the most entophobic visitors.

Members of the public are invited to the 2018 BugFest on October 20, 2018, at The North Carolina Museum of Natural History located at 11 West Jones Street, Raleigh, NC 27601. Admission is free. Parking is available in six lots nearby, and free street parking will also be available throughout the city on the day of the event. With more than 30,000 people expected again this year, visitors are encouraged to consider alternative transit options (https://naturalsciences.org/calendar/bugfest/getting-here-and-parking/).

# # #

About The North Carolina Museum of Natural History
The North Carolina Museum of Natural Sciences in downtown Raleigh (11 and 121 W. Jones St.) is an active research institution that engages visitors of every age and stage of learning in the wonders of science and the natural world. Hours: Mon.– Sat., 9 a.m.–5 p.m., and Sun., noon–5 p.m. General admission is free. Visit the Museum online at www.naturalsciences.org. Emlyn Koster, PhD, Museum Director. BugFest is the largest bug-centric event in the country.

About Kepley BioSystems

Kepley BioSystems (KBI) is a North Carolina-based life sciences start-up operating out of Gateway University Research Park (GURP) in collaboration with the Joint School of Nanoscience and Nanoengineering (JSNN), comprised of a partnership between the North Carolina Agriculture and Technical State University (NCA&T) and the University of North Carolina at Greensboro (UNCG). KBI was founded in 2013 with a mission to emerge disruptive innovations to achieve global solutions. For more information, visit: http://www.kepleybiosystems.com/

Anthony Dellinger
Kepley BioSystems Incorporated
(703)675-0277
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Meet Cammie, the KBI Crayfish


Source: EIN Presswire

Aspen Regenerative Medicine Now Offering Umbilical Cord Stem Cells for Osteoarthritis

With new research supporting the effectiveness of umbilical cord stem cells on osteoarthritis, we take it as our responsibility to give patients the power to overcome this debilitating condition.”

— Dr. Julian Gershon

ASPEN, COLORADO, UNITED STATES, October 15, 2018 /EINPresswire.com/ — At the Aspen Institute of Anti-Aging and Regenerative Medicine, the latest developments in healing have been discovered by utilizing stem cell therapy in clinical treatments for osteoarthritis. The clinic offers multiple applications for stem cell treatment from skin rejuvenation to hair restoration, but one of the most significant advances in regenerative medicine is in orthopedic use. As an alternative to more aggressive treatments such as long-term medications and surgery, stem cell therapy sets the goal of restoring full mobility and function in its application with orthopedic patients. The reparative qualities in stem cells have shown positive interactions with tendon and ligament injuries and have become a popular method for healing sports injuries. For Dr. Julian Gershon, the founding practitioner of the Aspen Institute for Antiaging and Regenerative Medicine, the function that umbilical cord stem cells serve to treat joint inflammation can prove to be the key to putting an end to osteoarthritis associated joint pain.

The pain and restricted movement from osteoarthritis are due to the joint’s cartilage wearing down severely enough to result in the bones and joints grinding against each other. Dr. Gershon’s method for repairing joint cartilage and reducing inflammation is through using the healing properties of Umbilical cord blood stem cells. Using high-quality, medical grade umbilical cord cells and growth factors, to give a longer lasting effect and improve quality of life for those suffering from osteoarthritis. The mesenchymal stem cells, or MSCs, in Umbilical cord blood have the potential to regenerate articular cartilage and studies have confirmed that intra-articular injection of stem cells provide improved knee function and less pain with no adverse events. In fact, the MSCs found in Umbilical cord blood stem cells have shown an increase in knee cartilage volume, enhanced joint function and effective disease modification.

“With new research supporting the effectiveness of umbilical cord stem cells on osteoarthritis, we take it as our responsibility to give patients the power to overcome this debilitating condition,” Dr. Gershon states, reflecting on the growing influence that modern innovation has had on advancing medicine to the degree of reversing the damage from osteoarthritis. “We aim to ensure our orthopedic stem cell treatments take our patients’ safety and comfort into account, so it’s exciting to see what cell therapy can offer in giving them an option that takes both into consideration and remains effective.”

The dedication that Aspen Institute of Anti-Aging and Regenerative Medicine places into providing safe and efficient solutions to a wide array of joint issues has motivated them to give patients the opportunity to gain the upper hand over osteoarthritis. With many causes of orthopedic conditions being linked towards deteriorating cartilage, the function that umbilical cord stem cells serve to reinforce tissue is a beneficial measure that proactively rebuilds cartilage while offering pain relief to patients. The efforts that Dr. Gershon has made to incorporate umbilical cord stem cells and MSCs into treatment options have helped to reinforce Aspen Regenerative Medicine’s status as a game-changing practice that taps into the body’s regenerative qualities to assist patients in reaching their optimal health.

About Dr. Julian Robert Gershon Jr. DO, FAOASM ABAARM
Dr. Julian Robert Gershon Jr. DO, FAOASM ABAARM, founder of the Aspen Institute for Anti-Aging and Regenerative Medicine, is triple board certified in Family Medicine, Sports Medicine and Anti-Aging and Regenerative Medicine. Dr. Gershon received his medical degree from Kirksville College of Osteopathic Medicine and completed his internship at Flint Osteopathic Hospital in Flint, Michigan. He is board certified in Family Medicine and Sports Medicine by the American Osteopathic Board of Family Practice, is a fellow of the American Osteopathic Academy of Sports Medicine and served on their Board of Directors for twelve years. He served as the head team physician for University of North Texas for over twenty years, served as a resident physician at the U.S. Olympic training center in Colorado Springs, Colorado in 1993, was selected as a team physician for the U.S. Olympic Judo team from 1993-2000 and served as the team physician at the 1996 Olympics in Atlanta, Georgia and was selected to travel to Chile with the U.S. Freestyle ski team during the summer of 2006. In addition to serving as a team physician for local high schools in Northern Texas, he also covered many professional wrestling events for the WWE at their Dallas events and traveled with the Unlimited Hydroplane Racing Commission performing on-water rescue as well as attending to athletic and medical injury/illnesses for their drivers. Dr. Gershon recently was awarded a fellowship in Stem Cell therapy by the American Academy of Antiaging and Regenerative Medicine. This prestigious award signifies years of advanced stem cell training.

About Aspen Institute for Anti-Aging & Regenerative Medicine
The Aspen Institute for Antiaging & Regenerative Medicine Experience specializes in everything that anti-aging and regenerative medicine has to offer in the relaxed and beautiful mountain setting of Aspen, Colorado. With stem cell and PRP therapy, founder Dr. Julian R. Gershon, Jr., DO, FAOASM, ABAARM has personally performed regenerative therapy treatments for orthopedic procedures, hair restoration, and skin rejuvenation. Additionally, their all-inclusive program is personally tailored to each patient and includes stem cell therapy, bio-identical hormone therapy via our intensive age management program, PRP facial regeneration, PRP hair regeneration, PRP “O-shot” or “PRP P-shot” for male and female sexual function, IV nutrition and vitamin therapy with antioxidant glutathione, customized year-long vitamin and nutrient supplementation, telomere testing to determine biologic age and monitor aging process, genetic testing, food allergy analysis and an environmental toxin assessment. The Aspen Institute for Antiaging and Regenerative Medicine maintains an excellent reputation for their commitment to shifting the emphasis from disease-driven medicine to an optimal health medical practice, treating each of patients individually and safely recommending programs according to their specific situations. They strive to give each patient the experience they expect and deserve from a health professional with the goal to help patients live better and longer.

Dr. Julian Gershon
Aspen Institute for Anti-aging & Regenerative Medicine
970-201-1332
email us here


Source: EIN Presswire